Efficacy - Confidence in IOP Control
Long-term results from National University Hospital (NUHS), Singapore prospective clinical study1 showed:
33% IOP reduction at 18 months, N = 38 patients
61% med reduction (2.1 to 1.3)
73% success rate with 1.3 sessions
NUHS Clinical Study 2
Multi-Centre Respective Data 1,3
Excellent Safety Profile
The MicroPulse P3™ Glaucoma Device powered by the CYCLO G6™ Glaucoma Laser System enables a versatile procedure with multiple safety benefits:
Non-Incisional
Minimal to no inflammation post-op
Patient downtime is significantly low
Repeatable
Predictable
Pre Treatment
Post Treatment with MP3. No detectable evidence of tissue damage
Images courtesy of A/Professor Paul Chew, NUHS
2014 Randomized study shows MicroPulse P3™ Glaucoma Device has similar IOP reduction as G-Probe with higher success rate and no hypotony1
| MicroPulse TSCPC | TSCPC | |
|---|---|---|
| Pre-op IOP | 36.5 mmHg | 35.0 mmHg |
| N Total of 48 | 24 pts | 24 pts |
| Average Follow-up | 17.5 months | 17.5 months |
| IOP Reduction | 45% | 45% |
| Success Rate (75%29% | ||
| Prologed Hypotony | 0 | 5 |
| Mean # of Treatments | 1.6 | 1.3 |
